Collaboration grants Sirtex global use of innovative technology to develop novel imaging agent for interventional oncology
Sirtex Medical and Magle Chemoswed’s development and commercial agreement is focused on generating a novel imaging agent for use in the interventional oncology field. The development program will begin in Q3 of 2020. Sirtex will have the exclusive license and commercialization rights in the defined field of use. Magle Chemoswed maintains rights to its technology platform and to exclusively manufacture the product for supply to Sirtex.
"Our partnership with Magle Chemoswed marks an important step in our company growth, portfolio expansion and investment in patient-centered care worldwide," said Kevin R. Smith, Chief Executive Officer of Sirtex. "We’re honored to utilize this technology platform to advance innovative therapies for patients."
"This is an incredibly exciting collaboration with a recognized global leader in the industry. With Sirtex's expertise and experience, we will be able to move the project from development to regulatory approvals and commercialisation quickly, and we look forward to working together closely for optimal success," says Justin Pierce, Magle Chemoswed’s CEO.
"We're thrilled to begin the collaborative program with Magle Chemoswed to combine our resources and expertise," said Dr. Mark Turco, Global Chief Medical Officer and EVP, Research and Development of Sirtex. "This technology will open the door to new product development opportunities for the highest quality of patient care."
Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 45 countries. For more information, visit www.sirtex.com. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.